Renovacor (RCOR) Stock Price, News & Analysis

Company Overview

Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.

Key Stats

• Today's Range: $3.20 to $3.20
• 50-Day Range: $2.56 to $3.28
• 52-Week Range: $1.34 to $9.74
• Volume: N/A
• Average Volume: 30,033 shs
• Market Capitalization: $55.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RCOR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Renovacor own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Renovacor investors own include HubSpot (HUBS), ForgeRock (FORG), Sportradar Group (SRAD), Thoughtworks (TWKS), Confluent (CFLT) and Netflix (NFLX).

Company Calendar

• Today: 8/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NYSE:RCOR
• CIK: 1799850
• Web: renovacor.com
• Phone: 610-424-2650
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.10 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.88%
• Return on Assets: -48.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.60
• Quick Ratio: 6.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.47 per share
• Price / Book: 1.30

Miscellaneous

• Outstanding Shares: 17,269,000
• Free Float: 14,782,000
• Market Cap: $55.26 million
• Optionable: Not Optionable
• Beta: -0.28